1. Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex Femoropopliteal Artery Lesions: The Randomized VIASTAR Trial (Viabahn Endoprosthesis With PROPATEN Bioactive Surface [VIA] Versus Bare Nitinol Stent in the Treatment of Long Lesions in Superficial Femoral Artery Occlusive Disease) J Am Coll Cardiol. 2013;62(15):1320-1327. doi:10.1016/j.jacc.2013.05.079 Randomization and Follow-Up of Study Patients *Screening failures: patients with lesions 35 cm, no tibial run-off. †Incorrect treatment: percutaneous transluminal balloon angioplasty (PTA) only without any device placement, “spot stenting” with <50% covering of the lesion after PTA. ITT = intention-to-treat; TPP = treatment per-protocol. Figure Legend:

2. Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex Femoropopliteal Artery Lesions: The Randomized VIASTAR Trial (Viabahn Endoprosthesis With PROPATEN Bioactive Surface [VIA] Versus Bare Nitinol Stent in the Treatment of Long Lesions in Superficial Femoral Artery Occlusive Disease) J Am Coll Cardiol. 2013;62(15):1320-1327. doi:10.1016/j.jacc.2013.05.079 Clinical Improvement Categorized according to (A) Rutherford category and (B) walking distance (in meters) according to the walking impairment questionnaire (WIQ) of the VIA versus BMS in superficial femoral artery lesions of patients with symptomatic peripheral arterial disease. Relative frequencies are displayed as stacked bar plots. Range is between grade 3 (indicating markedly improved) and –3 (indicating markedly worsening). Abbreviations as in Figure 2. Figure Legend:

3. Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex Femoropopliteal Artery Lesions: The Randomized VIASTAR Trial (Viabahn Endoprosthesis With PROPATEN Bioactive Surface [VIA] Versus Bare Nitinol Stent in the Treatment of Long Lesions in Superficial Femoral Artery Occlusive Disease) J Am Coll Cardiol. 2013;62(15):1320-1327. doi:10.1016/j.jacc.2013.05.079 Patency Rate of Lesions ≥20 cm Primary patency of VIA (red) versus BMS (black) in superficial femoral artery lesions of patients with symptomatic peripheral arterial disease and lesions ≥20 cm. (A) ITT: at 12 months VIA: 71.3% (95% CI: 0.53 to 0.83) versus BMS: 36.8% (95% CI: 0.17 to 0.57; log- rank test p = 0.01). (B) TPP: at 12 months VIA: 73.3% (95% CI: 0.54 to 0.85) versus BMS: 33.3% (95% CI: 0.13 to 0.54; log-rank test p = 0.004). Abbreviations as in Figures 1 and 2. Figure Legend:

4. Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents for Complex Femoropopliteal Artery Lesions: The Randomized VIASTAR Trial (Viabahn Endoprosthesis With PROPATEN Bioactive Surface [VIA] Versus Bare Nitinol Stent in the Treatment of Long Lesions in Superficial Femoral Artery Occlusive Disease) J Am Coll Cardiol. 2013;62(15):1320-1327. doi:10.1016/j.jacc.2013.05.079 Patency Rate of All Lesions Primary patency of Viabahn endoprosthesis (VIA) (red) versus bare-metal stent (BMS) (black) in the superficial femoral artery lesions of patients with symptomatic peripheral arterial disease. (A) ITT: at 12 months VIA 70.9% (95% confidence interval [CI]: 0.58 to 0.80) versus BMS 55.1% (95% CI: 0.41 to 0.67; log-rank test p = 0.11). (B) TPP: at 12 months VIA 78.1% (95% CI: 0.65 to 0.86) versus BMS 53.5% (95% CI: 0.39 to 0.65) (hazard ratio 2.23 [95% CI: 1.14 to 4.34]; log-rank test p = 0.009). Abbreviations as in Figure 1. Figure Legend: